Clinical and pathological findings of IgA nephropathy following SARS-CoV-2 infection
- PMID: 38400937
- PMCID: PMC10894116
- DOI: 10.1007/s10238-023-01271-2
Clinical and pathological findings of IgA nephropathy following SARS-CoV-2 infection
Abstract
The features of IgA nephropathy (IgAN) after SARS-CoV-2 infection have not been well characterized. In this study, we compared the clinical and pathological characteristics of patients with IgAN who had experienced SARS-CoV-2 infection to those who had not. We conducted a retrospective study that enrolled 38 patients with biopsy-proven IgAN following SARS-CoV-2 infection with 4 months (post-SARS-CoV-2 infection group) and 1154 patients with IgAN prior to the pandemic (pre-SARS-CoV-2 infection group). Among the SARS-CoV-2 group cases, 61% were females. The average duration from SARS-CoV-2 infection to renal biopsy was 78.6 days. Prior to SARS-CoV-2 infection, the patients had different presentations of nephropathy. One patient had isolated hematuria, two had isolated proteinuria, twenty presented with both hematuria and proteinuria, and one patient had elevated serum creatinine. Additionally, there were eight cases with uncertain nephropathy history, and six cases did not have a history of nephropathy. Following SARS-CoV-2 infection, five patients experienced gross hematuria, one case exhibited creatinine elevation, and five cases showed an increase in proteinuria. The group of patients infected with SARS-CoV-2 after the COVID-19 pandemic exhibited older age, higher hypertension ratio and lower eGFR values compared to the pre-SARS-CoV-2 infection group. As for pathological parameters, a higher proportion of patients in the post-SARS-CoV-2 infection group exhibited a higher percentage of sclerotic glomeruli and glomerular ischemic sclerosis. There were no significant differences observed between the two groups in terms of therapy involving steroids, immunosuppressants, or RAS inhibitors. IgA nephropathy patients who were infected with SARS-CoV-2 were generally older and experienced more severe kidney damage compared to those without SARS-CoV-2 infection.
Keywords: Clinical features; IgA nephropathy; Pathological characteristics; SARS-CoV-2.
© 2024. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
IgA nephropathy with glomerular capillary IgA deposition following SARS-CoV-2 mRNA vaccination: a report of three cases.CEN Case Rep. 2022 Nov;11(4):499-505. doi: 10.1007/s13730-022-00707-0. Epub 2022 May 13. CEN Case Rep. 2022. PMID: 35562631 Free PMC article.
-
Clinicopathological features and outcomes of IgA nephropathy with hematuria and/or minimal proteinuria.Kidney Blood Press Res. 2015;40(2):200-6. doi: 10.1159/000368495. Epub 2015 Apr 6. Kidney Blood Press Res. 2015. PMID: 25924707
-
[Clinicopathological analysis of IgA nephropathy with crescentic formation in childhood].Zhonghua Er Ke Za Zhi. 2004 Jun;42(6):412-6. Zhonghua Er Ke Za Zhi. 2004. PMID: 15265422 Chinese.
-
Indian scenario of IgA nephropathy: a systematic review and meta-analysis.Afr Health Sci. 2021 Mar;21(1):159-165. doi: 10.4314/ahs.v21i1.21. Afr Health Sci. 2021. PMID: 34394293 Free PMC article.
-
Non-immunosuppressive treatment for IgA nephropathy.Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3. Cochrane Database Syst Rev. 2024. PMID: 38299639 Free PMC article.
Cited by
-
A case of de novo glomerulonephritis following COVID-19 in a patient with preexistent IgA vasculitis.CEN Case Rep. 2025 Apr;14(2):236-241. doi: 10.1007/s13730-024-00940-9. Epub 2024 Oct 13. CEN Case Rep. 2025. PMID: 39397227 Free PMC article.
References
MeSH terms
Grants and funding
- TJWJ2022MS005/Tianjin Health Science and Technology Project
- TJWJ2022MS005/Tianjin Health Science and Technology Project
- TJWJ2022MS005/Tianjin Health Science and Technology Project
- TJWJ2022MS005/Tianjin Health Science and Technology Project
- TJWJ2022MS005/Tianjin Health Science and Technology Project
- TJWJ2022MS005/Tianjin Health Science and Technology Project
- TJWJ2022MS005/Tianjin Health Science and Technology Project
- TJYXZDXK-071C/Tianjin Key Medical Discipline (Specialty) Construction Project
- TJYXZDXK-071C/Tianjin Key Medical Discipline (Specialty) Construction Project
- TJYXZDXK-071C/Tianjin Key Medical Discipline (Specialty) Construction Project
- TJYXZDXK-071C/Tianjin Key Medical Discipline (Specialty) Construction Project
- TJYXZDXK-071C/Tianjin Key Medical Discipline (Specialty) Construction Project
- TJYXZDXK-071C/Tianjin Key Medical Discipline (Specialty) Construction Project
- TJYXZDXK-071C/Tianjin Key Medical Discipline (Specialty) Construction Project
- SO.20220718TJ/Kidney Medical development research Fund
- SO.20220718TJ/Kidney Medical development research Fund
- SO.20220718TJ/Kidney Medical development research Fund
- SO.20220718TJ/Kidney Medical development research Fund
- SO.20220718TJ/Kidney Medical development research Fund
- SO.20220718TJ/Kidney Medical development research Fund
- SO.20220718TJ/Kidney Medical development research Fund
- 2019YFF0216502/National Key Research and Development Program of China
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous